Literature DB >> 18349373

Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice.

Gek-Yen Gladys Tan1, Yichun Liu1, Suppiah Paramalingal Sivalingam1, Siew-Hoon Sim1, Dongling Wang1, Jean-Charles Paucod2, Yves Gauthier2, Eng-Eong Ooi1.   

Abstract

Melioidosis is caused by the Gram-negative bacterium Burkholderia pseudomallei, whose portals of entry into the body include subcutaneous, ingestion and inhalation routes. Animal models play an important role in furthering our understanding of this disease, which is associated with high morbidity and mortality in susceptible subjects. Previous studies using intranasal inoculation showed a differential susceptibility to inhalational melioidosis in BALB/c and C57Bl/6 mice and attributed the difference to genetic factors and host response. However, a recent study found no difference in susceptibility when the two species of mice were exposed to nebulized bacteria. We sought to address this discrepancy by using a nasal route only, instead of whole-body aerosol exposure system. Employing three different clinical strains of B. pseudomallei and following the progression of disease development in both BALB/c and C57Bl/6 mice, we found that BALB/c mice were at least 10- to 100-fold more susceptible to infection than C57Bl/6 mice. Comparison of bacterial burdens in aerosol-challenged mice, at both the pulmonary and distant sites of infection, suggests that C57Bl/6 mice were more efficient in clearing the bacteria than BALB/c mice. In addition, a comprehensive study of a wide panel of chemokines and cytokines at the protein level demonstrated that hyperproduction of proinflammatory cytokines in aerosol-challenged BALB/c mice did not translate into better protection and survival of these mice, whereas a moderate increase in these proteins in aerosol-challenged C57Bl/6 mice was more beneficial in clearing the infection. This suggests that high levels of proinflammatory cytokines are detrimental and contribute to the immunopathogenesis of the infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349373     DOI: 10.1099/jmm.0.47596-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  52 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Natural history of inhalation melioidosis in rhesus macaques (Macaca mulatta) and African green monkeys (Chlorocebus aethiops).

Authors:  John J Yeager; Paul Facemire; Paul A Dabisch; Camenzind G Robinson; David Nyakiti; Katie Beck; Reese Baker; M Louise M Pitt
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

3.  Differences in Inflammation Patterns Induced by African and Asian Burkholderia pseudomallei Isolates in Mice.

Authors:  Tassili A F Weehuizen; Emma Birnie; Bart Ferwerda; Joris J T H Roelofs; Alex F de Vos; Martin P Grobusch; W Joost Wiersinga
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

Review 4.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

5.  Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis.

Authors:  Laura Conejero; Natasha Patel; Melanie de Reynal; Sara Oberdorf; Joanne Prior; Philip L Felgner; Richard W Titball; Francisco J Salguero; Gregory J Bancroft
Journal:  Am J Pathol       Date:  2011-05-05       Impact factor: 4.307

Review 6.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Sara K Bondi; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

7.  Pathogenesis of percutaneous infection of goats with Burkholderia pseudomallei: clinical, pathologic, and immunological responses in chronic melioidosis.

Authors:  Carl Soffler; Angela M Bosco-Lauth; Tawfik A Aboellail; Angela J Marolf; Richard A Bowen
Journal:  Int J Exp Pathol       Date:  2014-02-27       Impact factor: 1.925

8.  Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule.

Authors:  Andrew E Scott; Thomas R Laws; Riccardo V D'Elia; Margaret G M Stokes; Tannistha Nandi; E Diane Williamson; Patrick Tan; Joann L Prior; Timothy P Atkins
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

9.  Burkholderia pseudomallei Capsule Exacerbates Respiratory Melioidosis but Does Not Afford Protection against Antimicrobial Signaling or Bacterial Killing in Human Olfactory Ensheathing Cells.

Authors:  Samantha J Dando; Deepak S Ipe; Michael Batzloff; Matthew J Sullivan; David K Crossman; Michael Crowley; Emily Strong; Stephanie Kyan; Sophie Y Leclercq; Jenny A K Ekberg; James St John; Ifor R Beacham; Glen C Ulett
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

10.  Innate immune responses of pulmonary epithelial cells to Burkholderia pseudomallei infection.

Authors:  Siew Hoon Sim; Yichun Liu; Dongling Wang; Vidhya Novem; Suppiah Paramalingam Sivalingam; Tuck Weng Thong; Eng Eong Ooi; Gladys Tan
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.